Engineered to meet stringent international pharmacopeial limits and ANMAT dossier specifications, these core dual-agonist and neuro-protective peptides provide immediate commercial edge for formulation trials.
Navigating structural economic transitions, industrial clusters in Pilar and Rosario, and the imperative for direct-from-source API partnerships under national healthcare modernization.
Argentina possesses one of Latin America's most self-sufficient domestic pharmaceutical sectors, anchored in the industrial parks of Pilar, Munro, Vicente López, and Greater Rosario. Leading domestic laboratories produce over 60% of domestic finished formulations, demanding consistent, GMP-grade Active Pharmaceutical Ingredients (APIs) with zero batch variance.
With evolving macroeconomic measures and central bank frameworks (BCRA, ARCA customs documentation), Argentine sourcing managers are actively consolidating fragmented middleman procurement into direct factory relationships. Direct-from-manufacturer supply mitigates margin degradation and shields against sudden import latency.
The Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) is recognized as a Level IV Regional Reference Authority by PAHO/WHO. Registering peptide biosimilars, generics, and new chemical entities requires comprehensive Drug Master Files (DMF), complete sequence impurity characterization, and validation according to Disposición 3409/99.
From public tender programs managed by PAMI and provincial Obras Sociales to private clinical institutions, our specialized peptide APIs target major therapeutic demands.
With obesity and Type-2 Diabetes Mellitus placing growing fiscal burdens on Argentine healthcare organizations, domestic laboratories are developing generic and bio-superior pipelines targeting GLP-1/GIP co-agonists. Peptides like Mazdutide and Cargrilintide allow local developers to formulate dual-receptor, long-acting subcutaneous solutions that match international clinical efficacy at accessible local price points.
Teduglutide (GLP-2 analogue) addresses severe mucosal malabsorption and intestinal atrophy. Argentine hospitals and pediatric surgery centers in Córdoba and Buenos Aires require ultra-pure, endotoxin-depleted sterile powders. Controlling truncated impurities (des-Gly or truncated forms) guarantees high absorption restoration without invoking neutralizing immunogenic antibodies.
Vasopressin CAS: 50-57-7 represents an indispensable active substance across emergency and intensive care units nationwide. Used extensively to treat vasodilatory shock refractory to norepinephrine and severe gastrointestinal hemorrhage, our vasopressin API conforms strictly to Ph. Eur. / USP specifications with rigorously audited biological potency assays.
Thymosin Alpha-1 and Thymalin operate as key immunomodulatory agents widely integrated into post-viral recovery regimens, chronic hepatitis management, and adjuvant chemotherapy regimens across the Southern Cone. Providing robust batch-to-batch molecular confirmation via LC-MS ensures safe integration into large-scale injectable hospital supplies.
Semax CAS: 80714-61-0 holds strong interest among neurological research institutes (CONICET, University of Buenos Aires Faculty of Pharmacy and Biochemistry) and compounding institutions evaluating neurotrophic factor stimulation, stroke rehabilitation, and cerebrovascular ischemia recovery.
Molecules like BPC-157 and Thymosin β4 (TB-500) are synthesized with high chromatographic precision for clinical wound healing, tendon repair formulations, and veterinary biotechnology applications—a significant subsector given Argentina’s massive agricultural and equine sports sectors.
Overcoming European capacity crunches and high energy overheads through scalable multi-ton chemical synthesis in Hangzhou, delivering unmatched continuity to South America.
Global demand for metabolic and therapeutic peptides has surged exponentially, leading European contract manufacturers to prioritize massive commercial commitments for multinational originators. This leaves mid-sized and regional generic producers in Latin America exposed to lead times extending past 10–14 months, bottlenecking domestic launch schedules.
Our synthesis facility in Hangzhou controls raw materials directly from Fmoc-amino acids, specialized coupling reagents (HATU, HBTU, PyBOP), high-loading CTC resins, to proprietary side-chain protecting groups. This eliminates external upstream disruptions, insulating Argentine buyers from international spot-market price volatility.
Operating multi-ton automated solid-phase peptide synthesis (SPPS) reactors and industrial preparative HPLC purification columns (up to 600mm diameter) yields significant economies of scale. We deliver active substances at 35–50% lower total procurement cost than European equivalents, directly improving tender bidding viability within Argentina.
Transforming classical SPPS into high-yield, green hybrid processes that guarantee extreme chemical purity and regulatory safety.
For lengthy amino acid sequences exceeding 30 residues (such as Mazdutide and Teduglutide), we implement fragment condensation strategies. Pre-synthesized, highly purified protected fragments are coupled via Liquid-Phase Peptide Synthesis (LPPS), dramatically minimizing deletion sequences and simplifying downstream chromatographic purification.
While research grade peptides routinely carry residual trifluoroacetic acid (TFA), ANMAT and international pharmacopeias enforce strict limits on fluoride counter-ions. We utilize automated ion-exchange chromatography systems to guarantee complete conversion to pharmaceutical-grade acetate or hydrochloride salts, with residual TFA quantified at <0.1% by 19F-NMR / IC.
In line with evolving global environmental mandates and hazardous waste reduction protocols, our R&D engineering team is phasing out hazardous DMF/NMP usage in favor of greener alternatives such as 2-Methyltetrahydrofuran (2-MeTHF) and Cyrene. This reduces process carbon footprints while maintaining equivalent amino acid solubility and coupling kinetics.
Ensuring unbroken product integrity from factory exit to final release in Ezeiza (EZE), supported by full regulatory documentation.
We supply comprehensive Open and Closed parts of Drug Master Files formatted under ICH Common Technical Document (CTD) specifications. Modules include detailed synthetic routes, impurity purging validation, batch analytical records, method validation reports (ICH Q2(R1)), and long-term stability testing under ICH Zone IVb conditions (30°C / 75% RH).
Peptides are highly vulnerable to thermal degradation and humidity. We partner with specialized biopharmaceutical freight handlers providing unbroken 2°C–8°C or -20°C cryo-logistics with calibrated, USB-enabled digital temperature dataloggers. Direct transit corridors from Shanghai Pudong (PVG) to Ezeiza Ministro Pistarini (EZE) minimize transshipment hold-ups.
Our Latin America desk works alongside Argentine customs despachantes to ensure exact tariff classification (NCM codes), comprehensive Certificates of Analysis (CoA), non-hazardous chemical declarations, and compliance certificates to satisfy ARCA/AFIP and ANMAT pre-import authorizations without storage delays.
Analytical benchmarks and supply parameters configured for Argentine drug manufacturers, research institutions, and compounding leaders.
| Peptide API Name | CAS Registry No. | Therapeutic Class / Indication | Standard Purity (RP-HPLC) | Counter-Ion Format | Standard Pack / Batch Scale | Regulatory Support Files |
|---|---|---|---|---|---|---|
| Mazdutide | 2259884-03-0 | GLP-1R / GCGR Dual Co-Agonist (Obesity/T2D) | ≥ 98.5% | Acetate (Freeze-dried) | 100g, 500g, 5kg+ | Open DMF, CoA, Mass Spec, 1H-NMR |
| Semax | 80714-61-0 | ACTH(4-10) Heptapeptide (Neuroprotection) | ≥ 99.0% | Acetate salt | 50g, 250g, 1kg | CoA, HPLC, MS, Endotoxin Assay |
| MOTS-c | 1627580-64-6 | Mitochondrial-Derived Peptide (Metabolism) | ≥ 98.0% | Acetate / TFA-free | 10g, 100g, 500g | Structural Confirmation, Certificate |
| Cargrilintide | 1415456-99-3 | Long-acting Amylin Analogue (Weight Mgmt) | ≥ 98.5% | Acetate salt | 50g, 250g, 2kg | Impurity Profile, CoA, Route Map |
| Teduglutide | 287714-30-1 | GLP-2 Analogue (Short Bowel Syndrome) | ≥ 99.0% | Acetate (Lyophilized) | 10g, 50g, 500g | Full CTD Module 3, Stability Data |
| Vasopressin | 50-57-7 | Nonapeptide Pituitary Hormone (Hemodynamics) | ≥ 98.5% (USP/Ph. Eur.) | Acetate | 25g, 100g, 1kg+ | CEP ready, USP/EP dossier, Bioassay |
| Orforglipron | 2212020-52-3 | Non-peptide Oral GLP-1 Small Molecule | ≥ 99.0% | Free base / Tartrate | 100g, 1kg, 20kg | Process Validation, Tech Package |
| Thymosin β4 (TB-500) | 77591-33-4 | Actin-Sequestering 43-AA Peptide (Repair) | ≥ 98.5% | Acetate salt | 50g, 250g, 1kg | Identity MS, HPLC trace, Heavy Metals |
| BPC-157 | 137525-51-0 | Gastric Pentadecapeptide (Tissue Regeneration) | ≥ 99.0% | Acetate / Arginate salt | 100g, 500g, 5kg | Lot-specific CoA, Stability Profile |
| Bremelanotide (PT-141) | 189691-06-3 | Melanocortin Receptor Agonist (HSDD) | ≥ 99.0% | Acetate salt | 25g, 100g, 500g | ICH Analytical Validation Dossier |
| Thymosin Alpha 1 | 62304-98-7 | Thymic Immunomodulating 28-AA Peptide | ≥ 99.0% | Acetate (Bioburden tested) | 50g, 500g, 2kg | Open DMF, Endotoxin < 5 EU/mg |
| Thymalin | 63958-90-7 | Synthetic Thymic Polypeptide Complex | ≥ 98.0% | Lyophilized sterile cake | 50g, 250g, 1kg | Biological Activity Assay, Full CoA |
*Note: Official pricing fluctuates based on commercial order volume, target specification (counter-ion, endotoxin ceilings), and custom synthesis batch dimensions. Contact our sales office for valid, locked quotes for Argentine customs importation.
Manufactured under rigid process parameter control with multi-ton yearly synthetic throughput, ready for express deployment to Argentine clinical research and generic pipeline development.
Direct answers addressing technical parameters, cold-chain assurance, ANMAT compliance dossiers, and transaction structuring.
Thin